Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs ...

SHERWOOD PARK, AB, March 24, 2025 /CNW/ - (TSXV: VTX) - Vertex Resource Group Ltd. ("Vertex" or the "Company") reports its financial and operational results for the fourth quarter and year ended ...

Vertex doesn't pay a dividend at present, which is unusual among the "Big Pharma" sector. However, its stock is up nearly 60% on a five-year basis, and remarkably, up >150% since October 2021.

Vertex holds a dominant position in the CF market. Its CF sales continue to grow, driven by the demand growth of the blockbuster drug, Trikafta/Kaftrio, in younger age groups.

Vertex's pain trial hits endpoint but sinks stock as placebo comparison spooks investors By Nick Paul Taylor Dec 19, 2024 7:41am Vertex Pharmaceuticals pain drug clinical trial data Clinical Data ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

BOSTON-- (BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The ...

After collecting $2.65 billion in second-quarter revenues, representing a 6% uptick from last year’s second quarter, Vertex lifted its full-year sales guidance to a range of $10.65 billion to ...

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion. Analysts surveyed by Visible Alpha were looking for $4.19 and $2.83 ...

Two Saudi Arabian agencies signed on with Vertex Pharmaceuticals to help boost the countr | The Vertex agreement is part of the Saudi Kingdom’s plan to make itself a global biotech hub by 2040.